| |
Apply advanced AI/ML methodologies to improve equity through data-informed site selection. Learn how to meet your enrollment diversity goals in this new insight brief — Download now.
|
|
|
Tuesday, October 29, 2024 | 10am ET / 7am PT Join us for this webinar to dive into the optimization of transient transfection scale-up. Don’t miss this opportunity to enhance your scale-up processes with new solutions. Register now to secure your spot!
|
|
| By Angus Liu Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job in a new presentation. |
|
|
|
By Gabrielle Masson The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing varying results among patients. |
By Fraiser Kansteiner As part of a new round of layoffs, certain Takeda staffers at two Massachusetts sites are set to lose their jobs. This marks the third round of job cuts Takeda has initiated in the state since it revealed a large restructuring drive in May. |
By Nick Paul Taylor Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to sustained suppression of the virus out to 48 weeks in a midphase clinical trial. |
|
Wednesday, October 29, 2024 | 11am ET / 8am PT Real-world data is essential to gaining insights into a patient’s diagnostic journey. However, many pharma companies may not be using lab data to its full potential. Join us to discuss how today’s robust lab data sources can help improve patient access and time to treatment, leading to better patient outcomes. Register now.
|
|
By Angus Liu After falling short in a confirmatory clinical trial, Gilead Sciences has decided to withdraw Trodelvy as a bladder cancer treatment in the U.S. |
By Darren Incorvaia Merck & Co. is putting down $30 million cash to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset designed to take on the tough-to-treat brain cancer glioblastoma. |
By Andrea Park A group of U.S. senators are digging into the direct-to-consumer telehealth platforms launched by Eli Lilly and Pfizer this year, in search of any indication that the services could create conflicts of interest for prescribers. |
By Conor Hale Tarver had held the interim position since late July, when Jeff Shuren announced his retirement after 15 years in the post. |
By Kevin Dunleavy Two years after emerging with its initial funding round, CDMO Nucleus RadioPharma is going bicoastal, revealing expansions at two sites that the company believes will "significantly improve” market access to the promising cancer treatments. |
By Darren Incorvaia London-based GSK is crossing the pond to form a new lung disease research collaboration with Boston scientists. The Big Pharma is joining forces with researchers from the Center for Regenerative Medicine at Boston University and Boston Medical Center to develop new models for lung diseases like pulmonary fibrosis. |
Fierce podcastsDon’t miss an episode |
| | This week on "Podnosis," we examine why diverse viewpoints are essential for tackling the industry’s toughest challenges and how building real engagement serves as the bedrock for innovation. |
|
|---|
|
|
| WhitepaperDirect-To-Patient Cash Solutions for Pharma Manufacturers – learn how to leverage cash models strategically to mitigate access challenges and overcome the hurdles faced in today’s retail pharmacy environment. Sponsored by: KnippeRx |
| WhitepaperDiscover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results. Sponsored by: WCG |
| WhitepaperLearn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
| SurveyExplore the latest trends in compliance monitoring to help your team embrace proactive strategies in key areas of risk management. Stay ahead of the ever-evolving landscape and new policies to enhance your compliance program. Sponsored by: IQVIA |
| ResearchRead this case study to discover how programmatic EHR advertising can transform your omnichannel marketing strategy. Sponsored by: Veradigm |
| eBookNeed the superpowers to select the right lab equipment? Sponsored by: PHC Corporation of North America |
| WhitepaperTake a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects. Sponsored by: Lonza |
| WhitepaperHow can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter |
| WhitepaperCognizant, in partnership with Microsoft, have interviewed 200 medtech decision makers across the UK, Ireland, France, Germany and the USA to find out about what the future holds. A responsible AI framework is going to be key. Read our report to learn more. Sponsored by: Cognizant and Microsoft |
| WhitepaperUnlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
| WhitepaperOpen up unexpected opportunities. This digital story offers pharma marketers proactive strategies for helping patients discover and switch to treatments, even if they aren’t actively looking to make a change. Sponsored by: Healthline Media |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
